Analytical Data
-
Gene name
GDF7
- Application
-
Alternative Names
GDF-7, BMP12
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7Z4P5
-
Expression Region
Thr322~Arg450
-
Protein Length
Partial
-
Molecular Weight
18&16kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GDF7, or Growth Differentiation Factor 7, is a member of the BMP (Bone Morphogenetic Protein) family, involved in various biological processes including mesoderm formation, neural development, and cartilage formation. Its functions are particularly significant in musculoskeletal development and repair, making it a potential target for therapeutic interventions in conditions such as osteoarthritis and fractures. Research on GDF7 recombinant protein has gained momentum due to its ability to promote chondrogenesis—the process by which cartilage is formed—thereby offering possibilities for regenerative medicine applications. Scientists have been exploring its mechanism of action, signaling pathways, and interactions with other proteins to harness its regenerative capabilities effectively. Additionally, the ability to produce GDF7 as a recombinant protein facilitates the study of its properties and interactions in detail, providing insights into its role in tissue engineering and potential for enhancing bone and cartilage repair strategies. Understanding the therapeutic potential of GDF7 through recombinant technology may pave the way for new treatments to address degenerative diseases and injuries in the musculoskeletal system. As research advances, GDF7 could emerge as a key player in the development of innovative strategies for enhancing tissue regeneration and improving clinical outcomes.
